We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
- Authors
Mark, Michael; Moos, Roger von; Cathomas, Richard; Stoffel, Sandro; Gillessen, Silke; von Moos, Roger
- Abstract
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. We want to congratulate Mitchell and colleagues for their important retrospective analysis of the real-world use of bone modifying agents (BMAs) in metastatic hormone-sensitive prostate cancer ([1]). Our trial SAKK 96/12 (Reduse) ([6]) compares an application of denosumab of every 4 weeks vs every 3 months in patients with castration-resistant prostate cancer and breast cancer with bone metastases and has already accrued 1178 of 1380 patients (85%).
- Subjects
ANTIANDROGENS; BONE tumors; UROLOGICAL surgery; PROSTATE tumors
- Publication
JNCI: Journal of the National Cancer Institute, 2022, Vol 114, Issue 4, p635
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djab216